Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedMinor site release note: Revision: v3.3.2 replaces v3.2.0, with no changes to study content or visible page data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoChange DetectedA maintenance notice about government funding status and NIH operations has been deleted from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check41 days agoChange DetectedStudy status updated to Completed with primary completion date 2024-05-10 and study completion date 2024-05-10. Enrollment is reported as 203 participants.SummaryDifference0.4%

- Check69 days agoChange DetectedVersion bumped to v3.2.0 with an added government-operating-status notice; the previous v3.1.0 deletion indicates the page now reflects the updated version.SummaryDifference4%

- Check76 days agoChange DetectedUpdated page to v3.1.0; removed several drug-safety topic categories (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) and retained the previous version tag v3.0.2. Overall, a reorganization/relabeling rather than adding new core content.SummaryDifference0.5%

- Check91 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2; 'Back to Top' link removed.SummaryDifference0.2%

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.